« Previous
Next »
Journal of the American Society of Hypertension
Volume 3, Issue 6
, Pages
395-402
, November 2009
An evaluation of the efficacy of olmesartan medoxomil in Black patients with hypertension
To access this article, please choose from the options below
Supported by Daiichi Sankyo, Inc. Dr. Thomas D. Giles received grant/research support from Novartis. Dr. Giles serves as a consultant for Novartis, Forest Laboratories, Daiichi Sankyo, Inc., sanofi-aventis, Bristol-Myers Squibb, and NicOx. Dr. Suzanne Oparil is the recipient of grants-in-aid from Daiichi Sankyo, Inc., Forest Laboratories, Gilead, Novartis, Pfizer, and Takeda. Dr. Oparil is a consultant for Boehringer Ingelheim, Daiichi Sankyo, Inc., NicOx, Novartis, sanofi-aventis, and The Salt Institute. Drs. Antonia Wang and Robert Dubiel are both employees of Daiichi Sankyo, Inc.
PII: S1933-1711(09)00129-6
doi: 10.1016/j.jash.2009.09.002
© 2009 American Society of Hypertension. Published by Elsevier Inc. All rights reserved.
« Previous
Next »
Journal of the American Society of Hypertension
Volume 3, Issue 6
, Pages
395-402
, November 2009
